United States - English - NLM (National Library of Medicine)

lifsa drugs llc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), pyridoxal phosphate anhydrous (unii: f06sge49m6) (pyridoxal phosphate anhydrous - unii:f06sge49m6), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), methylcobalamin (unii: br1sn1js2w) (methylcobalamin - unii:br1sn1js2w), calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6z - dexivite tablets is a prescription dietary supplement for use throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years. dexivite tablets may be useful in improving the nutritional status of women prior to conception.

United States - English - NLM (National Library of Medicine)

lifsa drugs llc - ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - bentivite tablets is an orally administered prescription vitamin formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced folate supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed. contraindications: bentivite tablets are contraindicated in patients with a known hypersensitivity to any of the ingredients. do not take this product if you are presently taking mineral oil, unless directed by a doctor.

United States - English - NLM (National Library of Medicine)

lifsa drugs llc - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan is indicated for the treatment of hypertension in adults and children six years and older, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee

United States - English - NLM (National Library of Medicine)

lifsa drugs llc - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - lymepak is indicated for the treatment of early lyme disease (as evidenced by erythema migrans) due to borrelia burgdorferi in adults and pediatric patients 8 years of age and older weighing 45 kg and above. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lymepak and other antibacterial drugs, lymepak should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. lymepak is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. risk summary lymepak, like other tetracycline-class antibacterial drugs, may cause discoloration of deciduous teeth and reversible inhibition of bone growth when administered dur

United States - English - NLM (National Library of Medicine)

lifsa drugs llc - urea (unii: 8w8t17847w) (urea - unii:8w8t17847w) - for debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or prurient debris or eschar. urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. pro-39 urea cream is contraindicated in patients with known hypersensitivity to any of the listed ingredients.

United States - English - NLM (National Library of Medicine)

lifsa drugs llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - hydrocortisone lotion is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. hydrocortisone lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

lifsa drugs llc - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), iodoquinol (unii: 63w7ie88k8) (iodoquinol - unii:63w7ie88k8) - based on a review of a related drug by the national research council and subsequent fda classification for that drug, the indications are as follows: "possibly" effective: contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. final classification of the less-than-effective indications requires further investigation. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

United States - English - NLM (National Library of Medicine)

lifsa drugs, llc - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m 2 ) [see warnings and precautions (5.1)]. - hypersensitivity to metformin. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. risk summary limited data with metformin hydrochloride tablets in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see data ]. there are risks to the mother and fetus associated with poorly controlled diabetes melli

United States - English - NLM (National Library of Medicine)

lifsa drugs llc - ferrous sulfate (unii: 39r4tan1vt) (ferrous cation - unii:gw89581owr), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) -

United States - English - NLM (National Library of Medicine)

lifsa drugs llc - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including, propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine and butorphanol and cyclazocine. naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock. (see clinical pharmacology; adjunctive use in septic shock ). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to it or to any of the other ingredients in naloxone hydrochloride. naloxone hydrochloride is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride has not been reported. tolerance to the opioid antagonist effect of naloxone hydrochloride is not known to occur. first aid an